Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep 17;7(1):326.
doi: 10.1038/s41392-022-01173-x.

Cytotoxic innate lymphoid cells sense tumor-derived IL-15: a novel mechanism of cancer immunosurveillance

Tobias Franz #  1 , Jonas Negele #  1 , Sascha Kahlfuss  2   3   4   5
Affiliations
Comment

Cytotoxic innate lymphoid cells sense tumor-derived IL-15: a novel mechanism of cancer immunosurveillance

Tobias Franz et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Mechanism of ILC1 tumor immunosurveillance in renal cell carcinoma (RCC) and polyomavirus middle tumor antigen (PyMT) breast cancer: Human clear cell renal cell carcinoma (ccRCC) tumors are infiltrated by exhausted PD1+CD8+ T cells, making immune checkpoint blockade an effective therapy for ccRCC patients. Instead, human (purple) chromophobe cell RCC (chRCC) and murine (yellow) polyomavirus middle tumor antigen (PyMT) tumors are characterized by infiltration of ILC1s. E-cadherin expressing cancer cells produce IL-15 and regulate the expansion of tissue-resident cytotoxic ILC1s via IL-2/IL-15 receptor β chain activation, which secrete granzymes and hence control chRCC and PyMT tumor growth. The interaction of ILC1s with tumor cells is characterized by direct sensing, Ca2+ influx, and also the expression of TRAIL, NGK2D and NKp46 on ILC1s. The figure was in part created with Biorender
See this image and copyright information in PMC

Comment on

References

    1. Kansler ER, et al. Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. Nat. Immunol. 2022;23:904–915. doi: 10.1038/s41590-022-01213-2. - DOI - PMC - PubMed
    1. Dadi S, et al. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. Cell. 2016;164:365–377. doi: 10.1016/j.cell.2016.01.002. - DOI - PMC - PubMed
    1. Gao Y, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat. Immunol. 2017;18:1004–1015. doi: 10.1038/ni.3800. - DOI - PubMed
    1. Friedrich C, et al. Effector differentiation downstream of lineage commitment in ILC1 is driven by Hobit across tissues. Nat. Immunol. 2021;22:1256. doi: 10.1038/s41590-021-01013-0. - DOI - PMC - PubMed
    1. Bergamaschi C, et al. Heterodimeric IL-15 in cancer immunotherapy. Cancers. 2021;13:1–20. doi: 10.3390/cancers13040837. - DOI - PMC - PubMed

Publication types